201 |
Barriers and enablers to healthcare system uptake of direct oral anticoagulants for stroke prevention in atrial fibrillation: a qualitative interview study with healthcare professionals and policy makers in EnglandMedlinskiene, Kristina, Richardson, S., Petty, Duncan R., Stirling, K., Fylan, Beth 08 May 2023 (has links)
Yes / Objective: To better understand the factors influencing the uptake of direct oral anticoagulants (DOACs) across different health economies in National Health Service England from the perspective of health professionals and other health economy stakeholders.
Design: Qualitative interview study using a critical realism perspective and informed by the Diffusion of Innovations in Service Organisations model.
Setting: Three health economies in the North of England, United Kingdom.
Participants: Healthcare professionals involved in the management of patients requiring oral anticoagulants, stakeholders involved in the implementation of DOACs and representatives of pharmaceutical industry companies and patient support groups.
Intervention: Semistructured interviews (face-to-face or telephone) were conducted with 46 participants. Interviews were analysed using the Framework method.
Results: Identified factors having an impact on the uptake of DOACs were grouped into four themes: perceived value of the innovation, clinician practice environment, local health economy readiness for change, and the external health service context. Together, these factors influenced what therapy options were offered and prescribed to patients with atrial fibrillation. The interviews also highlighted strategies used to improve or restrict the uptake of DOACs and tensions between providing patient-centred care and managing financial implications for commissioners.
Conclusions: The findings contribute to the wider literature by providing a new and in-depth understanding on the uptake of DOACs. The findings may be applicable to other new medicines used in chronic health conditions. / This work presents research funded by the Pharmacy Research UK (grant number: PRUK-2018-GA-1-KM) and Leeds Teaching Hospitals NHS Trust (grant number: N/A).
|
202 |
Newly Diagnosed Atrial Fibrillation in Acute Myocardial Infarction / 急性心筋梗塞における新たに診断された心房細動Obayashi, Yuki 25 March 2024 (has links)
京都大学 / 新制・課程博士 / 博士(医学) / 甲第25164号 / 医博第5050号 / 京都大学大学院医学研究科医学専攻 / (主査)教授 石見 拓, 教授 大鶴 繁, 教授 江木 盛時 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
203 |
Detekce fibrilace síní v krátkodobých EKG záznamech / Detection of atrial fibrillation in short-term ECGAmbrožová, Monika January 2019 (has links)
Atrial fibrillation is diagnosed in 1-2% of the population, in next decades, it expects a significant increase in the number of patients with this arrhythmia in connection with the aging of the population and the higher incidence of some diseases that are considered as risk factors of atrial fibrillation. The aim of this work is to describe the problem of atrial fibrillation and the methods that allow its detection in the ECG record. In the first part of work there is a theory dealing with cardiac physiology and atrial fibrillation. There is also basic descreption of the detection of atrial fibrillation. In the practical part of work, there is described software for detection of atrial fibrillation, which is provided by BTL company. Furthermore, an atrial fibrillation detector is designed. Several parameters were selected to detect the variation of RR intervals. These are the parameters of the standard deviation, coefficient of skewness and kurtosis, coefficient of variation, root mean square of the successive differences, normalized absolute deviation, normalized absolute difference, median absolute deviation and entropy. Three different classification models were used: support vector machine (SVM), k-nearest neighbor (KNN) and discriminant analysis classification. The SVM classification model achieves the best results. Results of success indicators (sensitivity: 67.1%; specificity: 97.0%; F-measure: 66.8%; accuracy: 92.9%).
|
204 |
The Role of MicroRNA Regulation of Cardiac Ion Channel in ArrhythmiaLuo, Xiaobin 08 1900 (has links)
La fibrillation auriculaire (FA) est le trouble du rythme le plus fréquemment observé en pratique clinique. Elle constitue un risque important de morbi-mortalité. Le traitement de la FA reste un défi majeur en lien avec les nombreux effets secondaires associés aux approches thérapeutiques actuelles. Dans ce contexte, une meilleure compréhension des mécanismes sous-jacents à la FA est essentielle pour le développement de nouvelles thérapies offrant un meilleur rapport bénéfice/risque pour les patients. La FA est caractérisée par i) un remodelage électrique délétère associé le plus souvent ii) à un remodelage structurel du myocarde favorisant la récurrence et le maintien de l’arythmie. La diminution de la période réfractaire effective au sein du tissu auriculaire est un élément clef du remodelage électrique. Le remodelage structurel, quant à lui, se manifeste principalement par une fibrose tissulaire qui altère la propagation de l’influx électrique dans les oreillettes. Les mécanismes moléculaires impliqués dans la mise en place de ces deux substrats restent mal connus. Récemment, le rôle des microARNs (miARNs) a été pointé du doigt dans de nombreuses pathologies notamment cardiaques. Dans ce contexte les objectifs principaux de ce travail ont été i) d'acquérir une compréhension approfondie du rôle des miARNs dans la régulation de l’expression des canaux ioniques et ii) de mieux comprendre le rôle de ces molécules dans l’installation d’un substrat favorable a la FA.
Nous avons, dans un premier temps, effectué une analyse bio-informatique combinée à des approches expérimentales spécifiques afin d’identifier clairement les miARNs démontrant un fort potentiel de régulation des gènes codant pour l’expression des canaux ioniques cardiaques humains. Nous avons identifié un nombre limité de miARNs cardiaques qui possédaient ces propriétés. Sur la base de ces résultats, nous avons démontré que l’altération de l'expression des canaux ioniques, observée dans diverse maladies cardiaques (par exemple, les cardiomyopathies, l’ischémie myocardique, et la fibrillation auriculaire), peut être soumise à ces miARNs suggérant leur implication dans l’arythmogénèse.
La régulation du courant potassique IK1 est un facteur déterminant du remodelage électrique auriculaire associée à la FA. Les mécanismes moléculaires sous-jacents sont peu connus. Nous avons émis l’hypothèse que l'altération de l’expression des miARNs soit corrélée à l’augmentation de l’expression d’IK1 dans la FA. Nous avons constaté que l’expression de miR-26 est réduite dans la FA et qu’elle régule IK1 en modulant l’expression de sa sous-unité Kir2.1. Nous avons démontré que miR-26 est sous la répression transcriptionnelle du facteur nucléaire des lymphocytes T activés (NFAT) et que l’activité accrue de NFATc3/c4, aboutit à une expression réduite de miR-26. En conséquence IK1 augmente lors de la FA. Nous avons enfin démontré que l’interférence in vivo de miR-26 influence la susceptibilité à la FA en régulant IK1, confirmant le rôle prépondérant de miR-26 dans le remodelage auriculaire électrique.
La fibrose auriculaire est un constituant majeur du remodelage structurel associé à la FA, impliquant l'activation des fibroblastes et l’influx cellulaire du Ca2 +. Nous avons cherché à déterminer i) si le canal perméable au Ca2+, TRPC3, jouait un rôle dans la fibrose auriculaire en favorisant l'activation des fibroblastes et ii) étudié le rôle potentiel des miARNs dans ce contexte. Nous avons démontré que les canaux TRPC3 favorisent l’influx du Ca2 +, activant la signalisation Ca2 +-dépendante ERK et en conséquence activent la prolifération des fibroblastes. Nous avons également démontré que l’expression du TRPC3 est augmentée dans la FA et que le blocage in vivo de TRPC3 empêche le développement de substrats reliés à la FA. Nous avons par ailleurs validé que miR-26 régule les canaux TRPC3 en diminuant leur expression dans les fibroblastes. Enfin, nous avons montré que l'expression réduite du miR-26 est également due à l’activité augmentée de NFATc3/c4 dans les fibroblastes, expliquant ainsi l’augmentation de TRPC3 lors de la FA, confirmant la contribution de miR-26 dans le processus de remodelage structurel lié à la FA.
En conclusion, nos résultats mettent en évidence l'importance des miARNs dans la régulation des canaux ioniques cardiaques. Notamment, miR-26 joue un rôle important dans le remodelage électrique et structurel associé à la FA et ce, en régulant IK1 et l’expression du canal TRPC3. Notre étude démasque ainsi un mécanisme moléculaire de contrôle de la FA innovateur associant des miARNs. miR-26 en particulier représente apres ces travaux une nouvelle cible thérapeutique prometteuse pour traiter la FA. / Atrial fibrillation (AF) is the most frequently-encountered arrhythmia in clinical practice and constitutes a major cause of cardiac morbidity and mortality. The management of AF remains a major challenge as current therapeutic approaches are limited by potential adverse effects and high rate of AF recurrence/persistence. A better understanding of the mechanisms underlying AF is of great importance to improve AF therapy. AF is characterized by impaired electrical and structural remodeling, both of which favors the recurrence and maintenance of the arrhythmia. A key feature in electrical remodeling is the reduced atrial effective refractory period, due to ion channel alteration. Structural remodeling, on the other hand, mainly results from atrial fibrosis. However, the precise molecular mechanisms underlying these remodeling processes are still incompletely understood. The importance of microRNAs (miRNAs) in various pathophysiological conditions of the heart has been well established, but little is known with regard to cardiac arrhythmias. Emerging evidence suggests that dysregulation of miRNAs may underlie heart rhythm disturbances. The aim of the present work was to acquire a comprehensive understanding of miRNA-mediated regulation of ion channels in cardiac arrhythmias. Notably, we will focus on the mechanistic insights of miRNAs related to the control of AF.
Currently available experimental approaches do not permit thorough characterization of miRNA targeting. For this purpose, we performed bioinformatic analyses in conjunction with experimental approaches to identify miRNAs from the database that potentially regulate human cardiac ion channel genes. We found that only a subset of miRNAs target cardiac ion channel genes. Based on these results, we further demonstrated that the dysregulation of ion channel gene expression observed in various cardiac disorders (e.g. cardiomyopathy, myocardial ischemia, and atrial fibrillation) can be explained by the dysregulation of miRNAs. These findings further support the potential implication of miRNAs in arrhythmogenesis under these cardiac conditions.
The upregulation of the cardiac inward rectifying potassium current, IK1, is a key determinant of adverse atrial electrical remodeling associated with AF. The molecular mechanisms underlying this ionic remodeling are poorly understood. We hypothesized that altered miRNA expression is responsible for IK1 upregulation in AF. We found that miR-26 is significantly downregulated in AF and regulates IK1 by controlling the expression of its underlying subunit Kir2.1. Moreover, we demonstrated that miR-26 is under the transcriptional repression of the nuclear factor of activated T cells (NFAT) and enhanced activities of members of the NFAT family, NFATc3/c4, results in miR-26 downregulation, which accounts for IK1 enhancement in AF. Furthermore, we observed that in vivo interference of miR-26 affects AF susceptibility via the regulation of IK1, suggesting an important role of miR-26 in atrial electrical remodeling.
Atrial fibrosis is a major constituent in AF-associated adverse atrial structural remodeling, involving the activation of fibroblasts and cellular Ca2+ entry. Here, we sought to determine whether the Ca2+ permeable channel, TRPC3, plays a role in AF-induced fibrosis by promoting fibroblast activation. Furthermore, we investigated the potential role of miRNAs in this context. We found that TRPC3 channels promote Ca2+-entry, which results in activation of Ca2+-dependent ERK-signaling and consequently fibroblast activation. We also demonstrated that TRPC3 is upregulated in AF and in vivo TRPC3 blockade suppresses the development of AF-promoting substrate. Furthermore, we observed that miR-26 regulates TRPC3 channels via controlling the expression of the underlying channel subunit and is downregulated in AF-fibroblasts. Finally, we showed that the reduced expression of miR-26 is also due to the enhanced NFATc3/c4 activities in AF-fibroblasts and accounts for AF-induced upregulation of TRPC3, suggesting the potential contribution of miR-26 in AF-related adverse structural remodeling process.
In conclusion, our findings emphasize the importance of miRNAs in the regulation of cardiac ion channels. Notably, miR-26 plays a crucial role in AF-associated electrical and structural remodeling via the regulation of IK1 and TRPC3 channel genes. Thus, our study unravels a novel molecular control mechanism of AF at the miRNA level, suggesting miR-26 as a new and promising therapeutic target for AF.
|
205 |
Natriuretische Peptide bei Vorhofflimmern und Herzinsuffizienz in Diast-CHF / Eine prospektive Beobachtungsstudie über neun Jahre / Natriuretic peptide in atrial fibrillation and heart failure in Diast- CHF / Prospective observation study for nine yearsBecker, Christian 13 August 2019 (has links)
No description available.
|
206 |
Aspectos genéticos da fibrilação atrial isolada / Genetic aspects of lone atrial fibrillationPessente, Gabrielle D'Arezzo 14 June 2019 (has links)
A fibrilação atrial (FA) é a arritmia cardíaca sustentada mais comum, de origem supraventricular, em que ocorre uma completa desorganização na atividade elétrica atrial, fazendo com que os átrios percam sua capacidade de contração, não gerando sístole atrial. É uma arritmia que acomete 1-2% da população mundial, sendo mais frequente em indivíduos idosos. Geralmente, está associada a algum tipo de doença cardíaca estrutural, podendo acarretar em complicações como o acidente vascular cerebral, internações e gastos com saúde. Algumas vezes a fibrilação atrial surge de forma precoce, em indivíduos jovens, saudáveis, e sem qualquer evidência de doença cardíaca estrutural ou de fatores desencadeantes, o que leva a hipótese da doença ter um componente genético. Trata-se de um estudo observacional, transversal, para identificação de possíveis variantes genéticas em pacientes portadores de fibrilação atrial isolada, a partir do sequenciamento de nova geração de um painel genético customizado para cardiomiopatias e canalopatias hereditárias. Foram incluídos 101 pacientes encaminhados pelo ambulatório de arritmias cardíacas do Instituto do Coração, que foram avaliados quanto às características clínicas principais antes de serem submetidos ao teste genético. A classificação das variantes em genes causais foi baseada nos critérios do American College of Medical Genetics and Genomics (ACMG). Foram sequenciadas e analisadas amostras de 101 pacientes, onde foram encontradas 144 variantes raras; 14/144 foram classificadas como patogênicas em relação à fibrilação atrial, 130/144 foram classificadas como de significado incerto, e em 28 dos 101 pacientes não foram encontradas variantes raras. Dos 101 pacientes 77,2% eram do sexo masculino, 87,1 % de raça branca, 75,2 % tinham fibrilação atrial paroxística, 52,4 % eram sintomáticos, 65,3% realizaram procedimento de ablação por cateter e 62,4% tinham história familiar de FA precoce, morte súbita, marcapasso e/ou insuficiência cardíaca. A presença dos achados genéticos esteve associada nos pacientes com FA que tinham história familiar de marcapasso e/ou morte súbita. A análise genética desta população permitiu um diagnóstico precoce de miocardiopatias hereditárias que se apresentaram inicialmente como FA isolada / Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia of supraventricular origin, with a complete disorganization in the electrical activity of the atria, losing their capacity of contraction, not generating atrial systole. It is an arrhythmia that affects up to 2% of the world population, appearing more often in elderly individuals. It is usually associated with some types of structural heart disease, which can lead to complications such as stroke, hospitalizations and health costs. In some times atrial fibrillation emerges early, in younger healthy people, with no apparent evidence of structural heart disease or triggering factors, leading to the hypothesis that the disease has a genetic component. This is a cross-sectional, observational study to identify possible genetic variants in patients with isolated atrial fibrillation from new generation sequencing and a customized genetic panel for inherited cardiomyopathies and channelopathies. A total of 101 patients were referred and evaluated by the Cardiac Arrhythmias Outpatient Unit of the Heart Institute for the main clinical characteristics before being submitted to the genetic test. The classification of variants into causal genes was based on the American College of Medical Genetics and Genomics (ACMG) criteria. Samples were sequenced and analyzed from 101 patients, were found 144 rare variants; 14/144 were classified as pathogenic in relation to atrial fibrillation and 130/144 were classified as uncertain significance, and in 28 of 101 patients no rare variants were found. Of the 101 patients, 77.2% were males, 87.1% were white, 75.2% had paroxysmal atrial fibrillation, 52.4% were symptomatic, 65.3% had a catheter ablation procedure, and 62.4% had a family history of early AF, sudden death, pacemaker and/or heart failure. The presence of genetic findings was associated in patients with AF who had a family history of pacemaker and / or sudden death. The genetic analysis of this population allowed an early diagnosis of hereditary cardiomyopathies that initially presented as isolated AF
|
207 |
Ablação por radiofreqüência da fibrilação atrial paroxística: fatores determinantes da eficácia clínica a longo prazo / Radiofrequency catheter ablation of paroxysmal atrial fibrillation: decisive factors of the clinical efficacy in long-term.Sartini, Raul José Pádua 30 May 2007 (has links)
O objetivo deste estudo foi avaliar retrospectivamente, em longo-prazo, os preditores de recorrência de fibrilação atrial paroxística (FA) em 139 pacientes submetidos à ablação por radiofreqüência, através das técnicas ostial ou extraostial de abordagem do átrio esquerdo, associadas ou não à ablação do istmo cavo-tricuspídeo (ICT). Variáveis pré, intra e pós-ablação foram avaliadas por análise uni e multivariada, para determinar os preditores de recorrência da FA após um procedimento. Observou-se que maior tempo de história de FA, uso de mais antiarrítmicos e recorrência de FA dentro de 60 dias pós-procedimento, aumentaram o risco de recorrência de FA a longo-prazo. Por outro lado, a associação de flutter atrial e a ablação concomitante do ICT, reduziram o risco de recorrência ao final de 33 ±12 meses. / The objective of this study was to evaluate in retrospect, in long-term, the predictors of late recurrence of atrial fibrillation (AF) in 139 patients submitted to the ablation by radiofrequency, through the techniques ostial or extra-ostial of approach of the atrium left, associated or not to the ablation of the cavotricuspid isthmus(ICT). Variables pre, intra and post-ablation were appraised for analysis uni and multivariated, to determine the predictors of recurrence of AF after one procedure. It was observed that larger time of history of AF, use of more drugs and recurrence of AF within 60 days after procedure; they increased the risk of recurrence of AF in long-term. On the other hand, the association of atrial flutter and the concomitant ablation of ICT, they reduced the recurrence risk at the end of 33 ±12 months.
|
208 |
Prevalência e importância cardiovascular dos distúrbios respiratórios do sono na miocardiopatia hipertrófica / Prevalence and cardiovascular importance of sleep disordered breathing in patients with hypertrophic cardiomyopathyPedrosa, Rodrigo Pinto 25 October 2010 (has links)
Introdução: A miocardiopatia hipertrófica é a mais frequente doença cardiovascular de origem genética e está associada a arritmias e morte cardiovascular. O aumento do átrio esquerdo e a fibrilação atrial são considerados marcadores de morte por insuficiência cardíaca em pacientes com miocardiopatia hipertrófica. A apneia obstrutiva do sono é o distúrbio respiratório do sono mais comum, caracterizando-se por episódios recorrentes de colapso parcial ou total das vias aéreas superiores durante o sono. A apneia obstrutiva do sono é muito prevalente entre as populações com doença cardiovascular, como hipertensão arterial e insuficiência cardíaca, e está associada a remodelamento cardíaco e arritmias. Objetivos: O objetivo deste estudo foi determinar a prevalência dos distúrbios respiratórios do sono em pacientes com miocardiopatia hipertrófica e avaliar a associação da apneia obstrutiva do sono com o remodelamento cardíaco (ventricular e atrial) e fibrilação atrial em pacientes com miocardiopatia hipertrófica. Métodos: Foram estudados pacientes consecutivos estáveis clinicamente, com um diagnóstico confirmado de miocardiopatia hipertrófica acompanhados no Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Os pacientes foram submetidos à avaliação clínica, questionário de sonolência, bioquímica sanguínea, ecocardiograma e monitorização respiratória noturna com poligrafia portátil. Foi utilizado um valor de corte de 15 e 30 apneias e hipopneias por hora de registro para o diagnóstico de apneia obstrutiva do sono e apneia obstrutiva do sono grave, respectivamente. Resultados: Foram avaliados 80 pacientes consecutivos com miocardiopatia hipertrófica. Apneia obstrutiva do sono foi diagnosticada em 32 pacientes (40%). Apneia obstrutiva do sono grave esteve presente em 17 pacientes (21%). Pacientes com apneia obstrutiva do sono foram significativamente mais velhos (56 [41-64] vs. 39 [30-53] anos, p < 0,001), apresentaram maior índice de massa corporal (28,2 ± 3,5 vs. 25,2 ± 5,2 Kg/m2, p < 0,01), maior dimensão do átrio esquerdo (45 [42-53] vs. 41 [39-47] mm, p = 0.01) e maior diâmetro da aorta (34 [30-37] vs. 29 [28-32] mm, p < 0,001) em comparação com pacientes sem apneia obstrutiva do sono. Dois modelos de regressão linear múltipla para identificar os fatores associados ao aumento do átrio esquerdo e da aorta ascendente mostraram que o índice de apneia e hipopneia foi a única variável associada ao aumento atrial (p = 0,05) e da aorta (p = 0,01), respectivamente. A fibrilação atrial permanente esteve presente em 31% vs. 6% dos pacientes com e sem apneia obstrutiva do sono, respectivamente (p < 0,01). A apneia obstrutiva do sono (p = 0,03) e o diâmetro do átrio esquerdo (p = 0,03) foram os únicos fatores independentemente associados à fibrilação atrial em um modelo multivariado. Conclusão: A apneia obstrutiva do sono é muito prevalente em pacientes com miocardiopatia hipertrófica e está associada com aumento do átrio esquerdo e da aorta ascendente. A apneia obstrutiva do sono está independentemente associada à fibrilação atrial, um fator de risco para óbito cardiovascular nesta população / Background: Hypertrophic cardiomyopathy is the most common genetic cardiovascular disease and is associated with arrhythmias and cardiovascular death. Left atrial enlargement and atrial fibrillation are considered markers for death due to heart failure in patients with hypertrophic cardiomyopathy. Obstructive sleep apnea is the most common sleep disordered breathing and is characterized by recurrent episodes of partial or complete collapse of the upper airway during sleep. Obstructive sleep apnea is extremely prevalent among populations with cardiovascular disease, such as systemic hypertension and heart failure and is independently associated with heart remodelling and arrhythmias. Objectives: The aim of this study was to determine the prevalence of sleep disordered breathing in consecutive patients with hypertrophic cardiomyopathy and evaluate the association of obstructive sleep apnea with heart remodelling (ventricular and atrial) and with atrial fibrillation in patients with hypertrophic cardiomyopathy. Methods: We studied consecutive clinically stable patients with a confirmed diagnosis of hypertrophic cardiomyopathy followed in the Heart Institute Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, by clinical evaluation, sleep questionnaire, biochemical blood analysis, echocardiography and sleep study (overnight portable respiratory monitoring). We used a cut-off value of 15 and 30 apneas and hypopneas per hour of recording in the sleep study for the diagnosis of obstructive sleep apnea and severe obstructive sleep apnea, respectively. Results: We evaluated 80 consecutive patients with hypertrophic cardiomyopathy. Obstructive sleep apnea was present in 32 patients (40%). Severe obstructive sleep apnea was present in 17 patients (21%). Patients with obstructive sleep apnea were significantly older (56 [41-64] vs. 39 [30-53] years, p < 0.001), presented higher body mass index (28.2 ± 3.5 vs. 25.2 ± 5.2 Kg/m2, p < 0.01), increased left atrial diameter (45 [42-53] vs. 41 [39-47] mm, p = 0.01) and aorta diameter (34 [30-37] vs. 29 [28-32] mm, p < 0.001) compared with patients without obstructive sleep apnea. Two models of stepwise multiple linear regression to identify variables associated with left atrial and ascending aorta enlargement showed that apnea-hypopnea index was the only variable associated with left atrial enlargement (p = 0.05) and aorta diameter (p = 0.01), respectively. Permanent atrial fibrillation was present in 31% vs. 6% in patients with and without obstructive sleep apnea, respectively (p < 0.01). Obstructive sleep apnea (p = 0.03) and left atrial diameter (p = 0.03) were the only factors independently associated with atrial fibrillation in a multivariate model. Conclusions: Obstructive sleep apnea is highly prevalent in patients with hypertrophic cardiomyopathy and it is associated with left atrial and ascending aorta enlargement. Obstructive sleep apnea is independently associated with atrial fibrillation, a risk factor for cardiovascular death in this population
|
209 |
Geschlechterunterschiede in Klinik und Verlauf der dilatativen KardiomyopathieBrunhuber, Claudia 18 February 2009 (has links)
Ziel der Studie war es, den Einfluss des Geschlechts auf die Klinik, die medikamentöse Therapie und den Gebrauch von Interventionen bei Patienten mit terminaler dilatativer Kardiomyopathie (DCM) nach Vorstellung zur Herztransplantation zu untersuchen. Es wurden 702 konsekutive DCM-Patienten (110 Frauen, 592 Männer) rekrutiert, die sich am Deutschen Herzzentrum Berlin zur Herztransplatation vorstellten und während eines Zeitraumes von im Mittel 4,3 Jahren beobachtet wurden. Die Diagnose DCM wurde durch Herzkatheter bestätigt. Etwa 300 Variablen zu Basisparametern, medikamentöser Therapie, Interventionen und Outcome wurden pro Patient analysiert. Der kombinierte Endpunkt wurde als das Auftreten eines von drei Ereignissen definiert: Tod auf der Warteliste, Herztransplantation oder Implantation eines Assist-Device. Die Ereignisanalyse wurde mittels multivariater Regression und Kaplan-Meier-Statistik durchgeführt. Bei Erstvorstellung zeigten Frauen und Männer keine Unterschiede in Alter, LVEF und LVEDD (% der Norm, für Alter und BSA korrigiert), aber bei Symptomatik, RVEF, linksatrialem Durchmesser, Vorhofflimmern und Beta1-Autoantikörpern. Frauen wurden signifikant früher transplantiert als Männer (112,3 +/- 117,5 vs. 340,7 +/- 332,1 Tage auf der Warteliste; p = 0,0001). Stärkste unabhängige Prädiktoren für Ereignisse bei beiden Geschlechtern waren korrigierter LVEDD und RVEF. Bei Frauen erhöhte Vorhofflimmern das Ereignisrisiko 3fach (2,905; CI: 1,406 - 6,001), wohingegen das Outcome bei Männern durch Vorhofflimmern nicht beinflusst wurde. Alter bei Erstvorstellung, Belastungsdyspnoe und Immunadsorption waren zusätzliche Prädiktoren bei Männern. Zusammenfassung: Geschlechterunterschiede bei klinischen Basisparametern können Behandlung und Outcome von DCM-Patienten beeinflussen. Vorhofflimmern ist bei männlichen Patienten nicht mit einem schlechteren Outcome assoziiert, bewirkt jedoch eine 3fache Erhöhung des Ereignisrisikos bei weiblichen Patienten. / The goal of this study was to determine the influence of gender on clinical parameters, on medical treatment and use of interventions in patients with end-stage dilated cardiomyopathy (DCM) presenting for heart transplantation. We enrolled 702 consecutive patients (592 men and 110 women) with DCM who presented at the German Heart Institute Berlin for heart transplantation and were followed for an average time of 4.3 years. Diagnosis of DCM was confirmed by cardiac catheterization. About 300 variables of baseline characteristics, medical treatment, interventions, and outcome per patient were analysed. The combined end point was defined as the occurrence of one of three events: death on the waiting list, heart transplantation or cardiac assist device implantation and was analyzed by multivariate regression and Kaplan- Meier-statistics. At presentation women and men did not differ in age, LVEF and LVEDD (% of normal, corrected for age and BSA) but in symptoms, RVEF, left atrial size, atrial fibrillation, and beta-adreno-receptor auto-antibodies. Women were transplanted significantly earlier than men (mean 112.3+/-117.5 vs 340.7+/- 332.1 days on the waiting list; p value 0.0001). Strongest independent predictors for events in both sexes were corrected LVEDD and RVEF. In women, AF increased the risk for events 3fold (2,905; CI: 1.406 – 6.001) whereas in men AF did not predict outcome. Age at first presentation, dyspnoea, and immunoadsorption were additional predictors in men. In patients with DCM, gender differences in baseline characteristics may influence management and outcome. Atrial fibrillation is not associated with a poorer outcome in men but threefold increases the risk in women.
|
210 |
Papel do monitoramento remoto contínuo na detecção e no manejo terapêutico da fibrilação atrial em idosos com marca-passo definitivo / Role of continuous remote monitoring to detect and in the management of atrial fibrillation in elderly pacemaker patientsLima, Carlos Eduardo Batista de 24 April 2012 (has links)
Introdução: a fibrilação atrial (FA) é a arritmia mais frequente na prática clínica estando associada à elevada taxa de morbidade e mortalidade. O risco de acidente vascular cerebral (AVC) apresenta-se aumentado em pacientes com FA e há evidência de aumento progressivo do risco com o avançar da idade. A detecção precoce da FA pode permitir a antecipação terapêutica e consequente redução de morbimortalidade. Vários recursos diagnósticos têm sidos utilizados com essa finalidade incluindo o marca-passo cardíaco definitivo (MPD) que permite armazenar registros de elevada frequência no canal atrial. Sistemas atuais de monitoramento remoto contínuo (MRC) do portador de MPD permitem a identificação e o envio diário à distância destes eventos armazenados pelo dispositivo. Objetivo: definir o papel do MRC na detecção e no manejo da FA em idosos portadores de MPD. Método: foi um estudo prospectivo e randomizado com seleção consecutiva de 300 idosos (60 anos ou mais) entre março/2007 e janeiro/2010, em ritmo sinusal e com indicação para implante ou troca de MPD. Os pacientes (P) foram randomizados para grupo de intervenção (GI) em monitoramento remoto contínuo (n=150) e grupo controle (GC) em seguimento convencional (n=150) com consultas agendadas para 30, 90, 180 dias e posteriormente a cada seis meses até dois anos de seguimento. No GI foram realizadas consultas extras motivadas por alertas automáticos de FA com duração mínima de 2,5 horas enviados pelo sistema de MRC. Resultados: o tempo de seguimento médio foi de 435 dias. Não houve diferença entre os grupos (GI x GC) em relação à idade (75,5 x 74,3 anos, p=0,44), sexo (feminino 54,7% x 57,4%, p=0,46), indicação do MPD (BAV 89,7% x 88,7%; p=0,84) e eventos clínicos (incidência de FA 25,3% x 19,3%, p=0,42; AVC 1,4% x 0%, p=0,44 e óbitos 8,6% x 5,3%, p=0,16). Houve mais documentação eletrocardiográfica da FA no GI (10%) em comparação ao GC (4%), p=0,027 e o MPD detectou corretamente a FA em 95,2% desses casos. O tempo para a primeira recorrência da FA foi de 79 x 128 dias; p=0,005. O número de dias em FA foi menor no GI (16 dias; IConf 95%: 8,89 a 23,18) em relação ao GC (51,9 dias; IConf 95%: 21,89 a 81,93), p=0,028. Baseados no escore CHADS2 houve mais pacientes com indicação para terapia antitrombótica no GI (p=0,008). Foram realizadas 55 consultas extras motivadas pelo sistema de MRC com necessidade de mudança terapêutica em 81% dos casos (36% antitrombóticos, 20% antiarrítmicos, 13% reprogramação MPD e 12% cardioversão). Conclusões: o MRC proporcionou menor tempo para a detecção da FA reduzindo o número de dias em arritmia devido à antecipação da terapêutica. Houve mais pacientes com documentação eletrocardiográfica da FA e submetidos à terapia antitrombótica no GI. Os alertas automáticos do sistema de MRC apresentaram importância clínica na maioria das consultas extras havendo necessidade de modificações na terapia antiarrítmica e antitrombótica, assim como na reprogramação do MPD. Os resultados deste estudo destacam o MRC como ferramenta auxiliar no manejo da FA em idosos portadores de MPD / Introduction: atrial fibrillation (AF) is the most common arrhythmia in clinical practice and it is related to high prevalence of morbidity and mortality. The annual risk of stroke is increased in AF patients especially with advancing age. Early AF detection should anticipate the management of AF which can reduces morbidity and mortality. Atrial high rate episodes device detected is a good diagnostic tool in PM carriers and these events can be sent daily to the doctor by continuous remote monitoring (CRM) systems. The aim of this study was to determine the role of CRM to detect and in the management of AF in elderly pacemaker patients. Method: It was a randomized and prospective study. Between March/2007 and January/2010 we selected 300 consecutive patients with an indication to atrioventricular pacemaker implantation or generator change. There were included patients in sinus rhythm with 60 years old or more. They were randomized in remote group (RG=150) and control (CG=150). Follow-up (FU) was scheduled in 30, 90 and 180 days and after, 6/6 months until two years. Patients in RG had extra appointment if automatic AF alerts (minimum AF burden of 2.5 hours) were sent by CRM. Results: FU mean time was 435 days. There were no difference between studied groups (RG vs. CG) in age (75.5 vs. 74.3 years, P=0.44); gender (female 54.7% vs. 57.4%, P=0.46); pacemaker indication due to sick sinus syndrome 10.3% vs. 11.3% and AV block 89.7% vs. 88.7%, P=0.84; AF incidence 25.3% vs. 19.3%, P=0.42; stroke 1.4% vs. 0%, P=0.44 and death 8.6% vs. 5.3%, P=0.16. AF was documented by electrocardiogram in 21 patients (RG=10% vs. CG=4%, P=0.027) and the pacemakers detected AF correctly in 95,2%. Median time to first AF recurrence was 79 vs. 128 days, P=0.005. The mean AF days was 16.0 (IC95%; 8.89 to 23.18) vs. 51.91 (IC95%; 21.89 to 81.93); P=0.028. According CHADS2 score, there were more patients with an antithrombotic therapy indication in RG (P=0.008). In 55 extra appointments, there was a therapy change in 81% of them (36% antithrombotic therapy, 20% arrhythmic therapy, 13% pacemaker programming and 12% electrical cardioversion). Conclusion: CRM allowed earlier AF detection which reduced AF days by anticipated therapy. In RG, the time to detection of first AF recurrence was lower than in the conventional approach. There were more AF documented by EKG and more patients with an indication to antithrombotic therapy in RG. Most of extra appointment needed a therapy change with regard to antithrombotic or antiarrhythmic therapy and device programming. The results of this study point out the CRM like a good auxiliary tool in the management of AF in elderly pacemaker patients
|
Page generated in 0.0186 seconds